🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Summary: At least 4 different snakes 🐍 (& the Gila monster 🦎) have contributed to drug development with their venom. The products of snake venom include: ACE inhibitors, GPIIb/IIIa inhibitors, GLP-1 agonists, & the test for Lupus Anticoagulant. #UnusualDrugDiscovery 17/

Marc Carrier JTH Such interesting results!👏 In liver disease, the🩸 risk goes ⬆️w INR 1.5-2, and doesn't matter so much w further elevation. W VKAs the⬆️the INR the⬆️the 🩸risk; exponentially. Did I get it right Kristen Sanfilippo? 😊

😮 30% of #CTEPH patients just walking around with Iliac vein compression. Thanks for bringing this to our attention Anjali Vaidya MD 🫀!

4/4: Here’s my summary on QT prolonging medications categorized by risk for Torsades de Pointes Link to how risk categories were determined: wolterskluwer.com/en/expert-insi… AZCERT runs CredibleMeds (free online database with list of QT prolonging meds)

On the one hand, 😲1.1% of patients with ONLY #DVT develop #CTEPH! On the other hand, in this medical claims database study, we would expect those with other types of #PH to develop DVT. Interesting study, nonetheless. The PERT Consortium® pubmed.ncbi.nlm.nih.gov/35861839/

Such a privilege to hear José L. Díaz-Gómez, MD, MAS, FCCM, FASE, NCC(UCNS) discuss the forefront of POCUS for RV assessment. Thank you Mass General Anesthesia Juan G. Ripoll, MD for hosting and inviting MGH Division of Pulmonary & Critical Care Medicine Harvard Pulmonary & Critical Care Fellowship! Top 10 key points 🧵⤵️

I think this could have a role in the future of medicine. #POCUS pubmed.ncbi.nlm.nih.gov/36443355/

Effect of hypoxia and acidemia on pulmonary vasoconstriction. Source: ncbi.nlm.nih.gov/pmc/articles/P… #PH

Important #POCUS #echofirst pitfall 🚨 TAPSE (tricuspid annular systolic plane excursion) reduces without reduction in RV function (RVOT VTI) in post cardiac surgery patients. 🔗jtcvs.org/article/S0022-… #MedEd #Nephpearls

As the expanding role of factor 11 inhibitors is studied in treatment and prevention of thrombosis, these agents are likely to make it to market. Here is a summary of different inhibitors. #VTE

Sometimes it's nice to see we are doing better than we used to in #PH ATS PC Assembly atsjournals.org/doi/10.1164/rc…

Tool to screen for early #PH-#ILD from Parikh R, et al. Pulm circ. 2022;12(4). Pulmonary Hypertension Journal Club #PAHJC Pulmonary Circulation

Such an interesting idea for a study. Application of Point-of-care Ultrasound for Screening Climbers at High Altitude for Pulmonary B-lines #POCUS escholarship.org/uc/item/2j4205…

Excited to be teaching at the SUNY Upstate POCUS Academy! Thanks for the invitation, Dr. Angela Love! @UpstateSims

Note drugs carfilzomib and mitomycin C have been moved into the definite association category for #PulmonaryHypertension #PAH #PH (from Kovacs G, et al. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. Published online August 29, 2024:2401324.)

🩺 Join us for "Venous Thrombosis Update 2025"! Enhance your knowledge on the latest in #VTE management. 🗓️ April 11, 2025 ⏰ 8:00 AM - 4:00 PM EST 📍 in-person NYU Langone Health & Livestreamed 📰 Agenda 👇 🔗 bit.ly/3DMfVyv #PCCM #Hematology #Meded #vascular #DVT #CME

Presented at #ACC25: Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of a composite of death from any cause, lung transplantation, or pulmonary arterial hypertension. Full ZENITH trial results: nej.md/4iYkLbj